prod:prod_dcx-login
Xpert® Xpress Strep A
Qualitative real-time PCR test providing accurate detection of Group A Streptococcus in as soon as 18 minutes.
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
XPRSTREPA-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
To accurately diagnose pharyngitis caused by Group A Streptococcus (GAS) due to increasing incidence and prevalence globally.
- Annually, 616 million people have GAS pharyngitis, more than 18.1 million people develop severe GAS disease and more than 517,000 people die due to severe GAS disease.1
- Literature shows 37% of children who presented with pharyngitis tested positive for GAS, however 56% of visits were associated with antibiotic prescriptions. Similarly, 18% of adults presented with pharyngitis caused by GAS, but 72% were treated with antibiotics.2
(1) The Global Burden of Group A Streptococcal Diseases. Lancet Infect Dis. 2005 Nov; 5(11):685-94.
(2) Fleming-Dutra KE, et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA. 2016 May 3;315(17):1864-73.;
(3) Workflow studies conducted by Cepheid Solutions demonstrate that a throat culture confirmation workup costs~ $9.13 per culture. (Average cost includes reagents, labor cost and time). Data on file.
(4) Shulman ST, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15;55(10):1279-82.
(2) Fleming-Dutra KE, et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA. 2016 May 3;315(17):1864-73.;
(3) Workflow studies conducted by Cepheid Solutions demonstrate that a throat culture confirmation workup costs~ $9.13 per culture. (Average cost includes reagents, labor cost and time). Data on file.
(4) Shulman ST, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15;55(10):1279-82.
The Solution
- Cepheid provides on-demand testing for Group A Strep in as soon as 18 minutes.*
- Careful selection of the target gene produces quality results
- Delivering accurate and timely results optimizes fast treatment decisions and eliminates the need to perform culture confirmation of negative results.
* Full test runtime is 24 minutes. Positive results available in as soon as 18 minutes with early assay termination.
The Impact
- Accurate diagnosis of GAS supports antimicrobial stewardship and may reduce the amount of patients inappropriately prescribed antibiotics.
- Gain testing efficiencies and reduce costs by eliminating culture confirmation testing.3, 5
- Reduce the risk of GAS complications such as rheumatic fever and glomerulonephritis.
- Improve patient satisfaction with quicker time to result and appropriate prescriptions.
(3) Workflow studies conducted by Cepheid Solutions demonstrate that a throat culture confirmation workup costs~ $9.13 per culture. (Average cost includes reagents, labor cost and time). Data on file.
# Follow-up testing by culture is required if the Xpert Xpress Strep A test result is negative and clinical symptoms persist, or there is an outbreak of acute rheumatic fever (ARF).
# Follow-up testing by culture is required if the Xpert Xpress Strep A test result is negative and clinical symptoms persist, or there is an outbreak of acute rheumatic fever (ARF).
Related Products
Xpert Xpress CoV-2 plus
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2
Xpert Xpress SARS-CoV-2
A rapid, near-patient test for the detection of the novel coronavirus that causes COVID-19.
Xpert MTB/RIF Ultra
Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis in less than 80 minutes
Xpert Xpress CoV-2/Flu/RSV plus
Actionable rapid respiratory results to meet the challenges of co-circulating respiratory viruses